Intrathecal Dexmedetomidine Pharmacology and Clinical Use

Pharmacological Properties

• Dexmedetomidine is a selective α-2 receptor agonist with sedative, analgesic/opioid sparing, and sympatholytic properties, as reported by the American Society of Critical Care Medicine 1, 2
• The elimination half-life of dexmedetomidine is approximately 1.8-3.1 hours in patients with normal liver function, according to the American Society of Critical Care Medicine 1, 2

Clinical Effects

• Dexmedetomidine produces minimal respiratory depression compared to other sedative agents, as noted by the American Gastroenterological Association and the American Society of Critical Care Medicine 1, 4

Side Effects and Safety Considerations

• The most common side effects of intrathecal dexmedetomidine are hypotension and bradycardia, as reported by the American Society of Critical Care Medicine 1, 2
• Patients with severe hepatic dysfunction have impaired dexmedetomidine clearance and may require lower doses, according to the American Society of Critical Care Medicine 1

Monitoring Requirements

• Continuous hemodynamic monitoring is essential due to the potential for hypotension and bradycardia, as recommended by the American Society of Critical Care Medicine 2
• Sedation assessment should be performed regularly as dexmedetomidine can cause sedation even when administered intrathecally, according to the American Society of Critical Care Medicine 1

Special Considerations

• Avoid intrathecal dexmedetomidine in hemodynamically unstable patients due to increased risk of hypotension, as advised by the American Society of Critical Care Medicine 5, 6